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Introduction: The real benefit of surgical treatment of small cell
lung cancer (SCLC) has never been demonstrated, mainly because
of the rarity of surgical cases and the difficulty in comparing surgical
and medical series for the different classifications systems used by
surgeons (tumor, node, metastasis) and medical oncologists and
radiotherapists (Veterans Administrations Lung Cancer Study
Group).
Materials and Methods: We prospectively assessed the utility of
surgery after chemotherapy (carboplatin plus VP16 with or without
ifosfamide) with or without radiotherapy in 23 patients with preop-
erative diagnosis of resectable stage I to IIIA SCLC. A median of
three (range: three to six) courses of chemotherapy were adminis-
tered. Five pneumonectomies, 12 lobectomies (seven sleeve resec-
tions), and two segmentectomies were performed, and all except one
received radical lymph node dissection. Four (17%) patients re-
ceived exploratory thoracotomy. Nine (39%) patients received post-
operative thoracic radiotherapy.
Results: Pathological stages were complete response in four pa-
tients, stage I in seven patients, stage II in seven patients, and stage
III in five patients. Thirty-day morbidity and mortality were 9% and
0%, respectively. Surgery-related mortality at 90 days was 9%.
Median follow-up was 19 months. Overall and local relapse rates
were 52% and 17%, respectively. Median overall and disease-free
survival were 24 and 12 months. Patients with complete response or
pathological stage I had a significantly better Kaplan–Meier survival
and lower incidence of relapse than those with more advanced
pathological stage (p  0.025 and 0.027, respectively, log rank).
Conclusions: Survival after chemotherapy and surgery in the series
correlated with pathological but not pretreatment stage. Only pa-
tients with pathological stage 0 or I disease seem to benefit from
surgical resection.
Key Words: Small cell lung cancer, Surgery, Chemotherapy, In-
duction treatment.
(J Thorac Oncol. 2007;2: 131–134)
The randomized Medical Research Council (MRC) studypublished in 1973 found that radiotherapy alone was
superior to radiotherapy plus surgery for limited small cell
lung cancer (SCLC).1 The MRC findings were supported by
Osterlind et al’s2 large retrospective study published in 1985.
Furthermore, the Lung Cancer Study Group randomized trial,
published in 1994, which compared radiotherapy with radio-
therapy plus surgery for the local treatment of SCLC after
chemotherapy, also found that surgery did not improve me-
dian or long-term survival.3 Nevertheless, some of these
studies had limitations. In the MRC study, only 48% of the
surgical arm received radical resection, and 18% received
exploratory thoracotomy only (the main diagnostic procedure
at the time). Similarly, in the Osterlind et al.2 study, only 33%
of patients received radical resection, and 10% were found to
be metastatic on postsurgery investigations.
Other studies, by contrast, have found surgical resec-
tion after chemotherapy useful in early-stage SCLC, partic-
ularly in stage I or II disease.4–9 Nevertheless, most of these
studies were retrospective and used various treatment com-
binations and patient-selection criteria. Thus, the role of
surgery, in addition to chemotherapy, in achieving local
control and in increasing survival in SCLC has not been
established.
We performed a single-center prospective study to
provide indications as to the utility of surgical resection after
chemotherapy, with or without thoracic irradiation, in pa-
tients with resectable stage I to IIIA SCLC. We assessed
survival, recurrences, treatment-related morbidity and mor-
tality, and, in more recent patients, the role of positron
emission tomography (PET) in preoperative staging.
MATERIALS AND METHODS
Between 1998 and 2004, all patients presenting at our
Thoracic Surgery Division with histologically or cytologi-
cally documented stage I to IIIA resectable SCLC, age over
18 years, Eastern Cooperative Oncology Group performance
status of 0 to 2, and a predicted postoperative forced expira-
tory volume in 1 second above 40% on spirometry were
included in a prospective study employing surgery after
systemic chemotherapy, with postoperative radiotherapy in
selected cases.
Preoperative staging included whole-body computed
tomography (CT) and bronchoscopy, with brain magnetic
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resonance imaging and abdominal ultrasonography in cases
of suspected lesion at the brain or liver level. Mediastinos-
copy or mediastiotomy was usually performed in patients
with mediastinal lymph nodes 1 cm on CT. PET was
performed for restaging after chemotherapy in recent cases.
At least three courses of carboplatin/cisplatin and VP16, with
or without ifosfamide, were administered to all patients.
Radical surgery included systematic lymph node dissection
according to the current International Association for the
Study of Lung Cancer guidelines.10 The procedure included
the removal of at least three hilar and interlobar nodes and
three mediastinal nodes from three stations, in which the
subcarinal was always included. Postoperative thoracic radio-
therapy was usually given to patients with pathologic medi-
astinal nodes after radical surgery, or unresectable or partially
resected disease.
Survival times, assessed from the day of surgery until
death or most recent follow-up, were estimated by the
Kaplan–Meier method and were compared by the log-rank
test.
RESULTS
Twenty-three consecutive patients (nine [39%] women;
median age, 64 years [range: 38–81] were enrolled. Clinical
stage before treatment was I in nine (39%) patients, II in five
patients (22%), and IIIA in nine patients (39%). Eight pa-
tients had clinical mediastinal involvement at chest CT, and
three of them underwent pathological confirmation of N2
disease (two mediastinoscopy and one mediastinotomy). All
patients received a systemic treatment consisting of cisplatin/
carboplatin associated with etoposide. Ifosfamide was also
combined in seven patients. In detail, 13 patients received
360 mg/m2 of etoposide plus carboplatin area under the curve
of 5,11 and three patients received 360 mg/m2 of etoposide
plus 80 mg/m2 of cisplatin. Seven patients received 300
mg/m2of carboplatin, 5 g/m2 of ifosfamide, and 360 mg/m2 of
etoposide. The median number of cycles was four (range:
three to six).
Clinical response to chemotherapy was assessable in 22
patients according to the Response Evaluation Criteria in
Solid Tumors.12 Nineteen (83%) patients responded. Among
them, five were complete responses (22%), 14 were partial
responses (64%), two had a stable disease (9%), and one
patient had tumor progression (5%). None of the patients
interrupted chemotherapy because of toxicity.
Nineteen (83%) patients underwent surgery with cura-
tive intent: pneumonectomy in five (22%), sleeve lobectomy
in eight (35%), lobectomy in four (17%), and segmentectomy
in two (8%); all but one of these received systematic lymph
node dissection. The remaining four (17%) patients received
exploratory thoracotomy only: one because of vertebral in-
vasion, two because of extensive mediastinal node involve-
ment, and one because of limited functional reserve in light of
the requirement for pneumonectomy.
Pathological stage was 0 (complete response to chemo-
therapy) in four patients (17% of total); I in seven patients
(30%), II in seven patients (30%), and III in five patients
(22%). Mixed histology (SCLC and NSCLC) was found in
two patients (9%). Table 1 reports the correspondence be-
tween clinical pretreatment stage and pathological stage.
Median postoperative hospitalization was 6.5 days.
Postoperative complications occurred in two (8.7%) patients
and included one hemothorax and one episode of cardiac
ischemia. Thirty-day mortality was 0%. Two (8.7%) patients
had fatal late complications: bronchovascular fistula with
hemorrhage into the airway 56 days after sleeve lobectomy,
and pulmonary embolism associated with pneumonia 3
months after right pneumonectomy.
Postoperative thoracic radiotherapy was given to nine
patients. Indications were exploratory thoracotomy in four
patients, mediastinal nodal metastasis in three, and hylar
nodal metastasis in two. Fields of irradiation included medi-
astinum and lung in four cases (exploratory thoracotomy;
mean doses: 60 Gy on lung and 50 Gy on mediastinum). Four
subjects received irradiation of mediastinum only (54 Gy),
one of them associated with subclavicular regions. Another
patient received prophylactic cranial irradiation (26 Gy) and
additional postoperative chemotherapy.
Median follow-up after surgery was 20 months.
Overall 2- and 3-year survival were 49% (95% CI,
22%–76%) and 25% (95% CI, 0%–61%), respectively. Me-
dian overall survival was 24 months (Figure 1) and correlated
with pathological stage (p  0.025 log rank) but not with
pretreatment clinical stage (p  0.6).
According to clinical stage, 2-year survival was 91%
(95 CI, 74%–100%) for stage 0 and I disease, and it was 14%
(95 CI, 0%–40%) for stage II and III disease (p  0.025)
(Figure 2).
Twelve (52%) patients relapsed, and four of them
(17%) had local recurrence. The brain was the most frequent
(39%) site of distant metastases.
The recurrence rate correlated significantly with patho-
logical stage: 18% in stage 0 and I disease; 71% in stage II,
and 100% in stage IIIA (p  0.046).
Median disease-free survival was 12 months (Figure 3),
and cumulative incidence of relapse was correlated with
pathological stage (stage 0 and I versus stage II and III; p 
0.027) (Figure 4).
TABLE 1. Clinical Tumor, Node, Metastasis Staging Related
to the Final Pathological Finding
cIA cIB cIIA cIIB cIIIA Total
0 1 — — 1 2 4
pIA 1 4 — — 1 6
pIB — 1 — — 1 2
pIIA 1 — — 2 1 4
pIIB — — — 1 1 2
pIIIA — 1 — — 3 4
pIIIB — — — 1 — 1
Total 3 6 — 5 9 23
Nine patients were preoperatively staged as IIIA, but six of them (67%) were
downstaged after surgery. p, pathological staging; c, clinical staging.
Veronesi et al. Journal of Thoracic Oncology • Volume 2, Number 2, February 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer132
DISCUSSION
Theoretical advantages of surgery as part of a multi-
modality approach to limited SCLC are that such an approach
(a) reduces local relapse rate, (b) provides immediate com-
plete response, (c) has no effect on bone marrow, and (d)
provides accurate tumor, node, metastasis staging.13 Further-
more, mixed histology is found in 7% to 20% of resected
SCLC after chemotherapy3,6,7,14; often, initial misdiagnosis
may occur, and potentially curable cases may remain un-
treated (more frequently typical or atypical carcinoids, or
large cell neuroendocrine tumor).
Despite these theoretical advantages, the real benefit of
surgical treatment has never been demonstrated, mainly be-
cause of the difficulty of performing randomized trials, the
rarity of surgical cases, and the difficulty of comparing
surgical and medical series for the different classifications
systems used by surgeons (tumor, node, metastasis) and
medical oncologists and radiotherapists (Veterans Adminis-
trations Lung Cancer Study Group). Retrospective surgical
series generally suggest that patients with stage I disease
benefit when surgery is added to induction or adjuvant che-
motherapy, but for clinical stage II and III disease, most
retrospective studies indicate that surgery provides no benefit,
although there are exceptions.4,5,9,15 Nevertheless, most sur-
gical series have used disparate treatment regimes and surgi-
cal resection criteria, and many have also had excessively
long referral periods.2,4,7,9,11,16
By contrast, the patients in the present series were
recruited prospectively during the last 5 years, staged with
modern procedures, and submitted to the same chemotherapy
regimen and type of surgical resection: therein lies the main
interest of our study. We were able to perform radical surgery
in most patients with acceptable morbidity and no 30-day
FIGURE 1. Overall (Kaplan–Meier) survival in 23 SCLC patients.
FIGURE 2. Kaplan–Meier survival according to pathological
stage in 23 SCLC patients. Stage 0 and I patients had signifi-
cantly better (p  0.025 log-rank test) survival than stage II
and III patients.
FIGURE 3. Disease-free survival curve in 23 patients with
SCLC.
FIGURE 4. Cumulative probability of relapse according to
pathological stage in 23 patients with SCLC. Patients with
pathological stage 0 or I had a significantly lower relapse
rate than those at stage II or III.
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mortality. Nevertheless, we found that patients who re-
sponded to chemotherapy were generally demanding surgical
cases because of the absence of anatomic planes and the
presence of major inflammation in tissues around hylar struc-
tures. Furthermore, demanding parenchyma-sparing resec-
tions, combined with bronchial and vascular reconstruction,
had to be employed in eight (35%) cases to avoid pneumo-
nectomy. Pneumonectomy was performed in only five (22%)
cases, a similar proportion to previous surgical series.7,16
Although overall survival was poor (25% at 3 years),
outcomes in the 11 patients with pathological stage 0 or I
were significantly better than those with stage II or III disease
(90% versus 20% at 2 years; p  0.025). Stage 0 and I
patients also had a significantly (p 0.027) lower cumulative
relapse rate than those at stages II and III. Of the nine patients
at clinical stage IIIA, six were downstaged after surgery
(67%) (two had complete responses, two had stage I, and two
had stage II disease), but it is important to note that only one
of them was free of disease at the time this article was written
(this patient had a complete response at surgery and received
postoperative prophylactic cranial irradiation).
These findings are similar to those of most other stud-
ies4,9,12,16 and suggest that it is worthwhile to offer surgery to
patients with early clinical N0 disease or to those with more
advanced disease downstaged to pN0 after induction chemo-
therapy. Patients with persistent N1 or N2 disease have poor
prognosis (70%–100% recurrence rate), even after multimo-
dality treatment.
We found that the brain was the site of most metastases,
suggesting that prophylactic brain irradiation should be given
to all responders. We also found that surgery provided good
local disease control in that only 17% of patients developed
a local recurrence. Nevertheless, similar local recurrence
rates have been obtained by recent chemoradiation trials.15,17
Our finding that survival correlated with pathological
stage after induction but not with clinical stage before induc-
tion suggests that patients with N2 disease who respond to
chemotherapy to become N0 may have a greater chance of
being cured than patients with N1 disease who do not respond
to induction chemotherapy. Because lymph node status is the
main predictor of survival,3,4,9,14,16,18 future study on the role
of PET scan for the selection of surgical candidates after
induction treatment19 would be worthwhile.
We conclude that patients with stage I SCLC or com-
plete nodal response after chemotherapy may benefit from
surgical resection. Those with persistent hylar or mediastinal
node involvement after chemotherapy have a poor prognosis
and are not recommended for surgery.
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